Glycoprotein P pharmacogenetic assessment role in digoxin pharmacotherapy individualization: a new approach for an old problem

The aim of the study was to investigate effects of glycoprotein P-coding gene MDR1 polymorphic marker C3435T on digitalis intoxication symptoms and plasma digoxin concentration increase in patient with persistent atrial fibrillation (AF). In 103 AF patients, genotyping by gene MDR1 polymorphic marker С3435T was performed in polymerase chain reaction (PCR). Balance plasma digoxin concentration was measured by polarizing fluoro-immune assay in 29 participants. Results: Plasma digoxin concentration was higher in TTgenotype patients, comparing to CC and CT genotype individuals (l,77 ± 0,17vs 1,17 ± 0,21, p = 0,02; 1,77 ± 0,17 vs 1,37 ± 0,30, p = 0,037, respectively). Glycoside intoxication syndromes were more prevalent in TTgenotype than in CC and CT genotypes (57 % vs 13 %, p = 0,0001, OR = 6,4, CI 1, 9-21,9). Therefore, TT genotype of glycoprotein P-coding gene MDR1 polymorphic marker C3435T, was associated more frequent symptoms of glycoside intoxication and higher plasma digoxin levels.

persistent atrial fibrillation, digitalis intoxication symptoms, plasma digoxin concentration increase, effects of glycoprotein PFcoding gene MDR1 polymorphic marker С3435Т

1. Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. М.: Реафарм, 2004, C. 113-120.

2. Середенин С.Б. Лекции по фармакогенетике. М.: МИА, 2004. 303 с.

3. Сидоренко Б.А., Преображенский Д.В., Шарошина И.А. и др. Место сердечных гликозидов в лечении хронической сердечной недостаточности. Часть I. Клиническая фармакология. Кардиология 2005; 4: 36-44.

4. Budowle В., Baechtel F.S. Modifications to improve the effectiveness of restriction fragment length polymorphism. Appl. Electrophor. 1990. Vol. 1. P. 181-187.

5. Hitzl M., Drescher S., van der Kuip H., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001 Jun; 11(4): 293-8.

6. Hoffmeyer S., Burk O., von Richter О., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 2000 Mar 28; 97(7): 3473-8.

7. Johne A., Kopke K., Gerloff T., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 2002 Nov; 72(5): 584-94.

8. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters. 2006; 234: 4-33.

9. Kurata Y., Ieiri I., Kimura M., et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 2002 Aug; 72(2): 209-19.

10. Marzolini, Paus, Buclin, Kim. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004; 75: 1.

11. Nakamura T., Sakaeda T., Horinouchi M., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 2002 Apr; 71(4): 297-303.

12. Siegsmund M., Brinkmann U., Schaffeler E., et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 2002 Jul; 13(7): 1847-54.

13. Oselin K., Gerloff T., Mrozikiewicz P.M., et al. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 2003 Aug; 17(4): 463-9.

14. Rathore S.S., Wang Y., Krumholz H.M. Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure. N. Engl. J. Med. 2002; 347: 1403-1411, Oct 31, 2002.

15. Verstuyft C., Schwab M., Schaeffeler E., et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 2003 Apr; 58(12): 809-12.